Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients
The serum CDC42 level associates with LNM, visceral metastasis, and worse prognosis in mCRPC patients underwent abiraterone plus prednisone therapy. However, future prospective, large-scale, and controlled studies are needed for validation.
Authors
- Zhihua Cao (ORCID: https://orcid.org/0000-0002-6143-1360)
- Xu Zhu (ORCID: https://orcid.org/0000-0002-4623-8458)
- Jianping Xiong (ORCID: https://orcid.org/0000-0003-0398-6090)
- Jiacheng Zhang (ORCID: https://orcid.org/0000-0001-5970-3200)
- Zhonghao Zhao
- Yong Ma
Institutions
- Songjiang District Central Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1007/s12672-025-02130-0
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52